Cargando…

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis

Detalles Bibliográficos
Autores principales:	Yamakawa, Kazuma, Levy, Jerrold H., Iba, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729086/ https://www.ncbi.nlm.nih.gov/pubmed/31488189 http://dx.doi.org/10.1186/s13054-019-2587-2

Ejemplares similares

Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015)

Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET
por: François, Bruno, et al.
Publicado: (2021)

Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin
por: Iba, Toshiaki, et al.
Publicado: (2018)

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
por: Iba, Toshiaki, et al.
Publicado: (2009)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC
por: Yamakawa, K, et al.
Publicado: (2014)

Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
por: Kato, Takahiro, et al.
Publicado: (2018)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
por: Iba, Toshiaki, et al.
Publicado: (2019)

Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy
por: Levi, Marcel, et al.
Publicado: (2020)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yoshimura, Jumpei, et al.
Publicado: (2015)

The coagulopathy, endotheliopathy, and vasculitis of COVID-19
por: Iba, Toshiaki, et al.
Publicado: (2020)

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey
por: Iba, Toshiaki, et al.
Publicado: (2017)

Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies
por: Kudo, Daisuke, et al.
Publicado: (2021)

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
por: Iba, Toshiaki, et al.
Publicado: (2022)

Comparison of the effects of recombinant human soluble thrombomodulin for systemic inflammatory response syndrome-associated coagulopathy with and without continuous hemodiafiltration
por: Matsuo, SM, et al.
Publicado: (2011)

Role of extracellular vesicles in the development of sepsis-induced coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2018)

Proposal of the Definition for COVID-19-Associated Coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2021)

Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
por: Iba, Toshiaki, et al.
Publicado: (2022)

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes
por: Hasegawa, Daisuke, et al.
Publicado: (2019)

Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)

Oh, how hard it is to open the gate for sepsis trials: lessons from SCARLET
por: Iba, Toshiaki, et al.
Publicado: (2018)

Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines
por: Iba, Toshiaki, et al.
Publicado: (2022)

The unique characteristics of COVID-19 coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2020)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries
por: Goto, Tadahiro, et al.
Publicado: (2022)

Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis
por: Wada, Takeshi, et al.
Publicado: (2022)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release
por: Akatsuka, Masayuki, et al.
Publicado: (2020)

Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy
por: Umemura, Yutaka, et al.
Publicado: (2020)

Diagnosis of sepsis‐induced disseminated intravascular coagulation and coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2019)

Intracellular communication and immunothrombosis in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2022)

Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2017)

Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients
por: Miyoshi, Seigo, et al.
Publicado: (2014)

Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis
por: Iba, Toshiaki, et al.
Publicado: (2020)

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study
por: Kato, Takahiro, et al.
Publicado: (2013)

Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery
por: Konishi, Hirotaka, et al.
Publicado: (2017)

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura
por: Nakamura, Kensuke, et al.
Publicado: (2016)

Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro
por: Shimomura, Yasuyo, et al.
Publicado: (2016)

Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin
por: Katayama, Shinshu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_afddjjdahvj01cve8plou34pbi